HC Wainwright Predicts Higher Earnings for Maze Therapeutics

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Maze Therapeutics from ($1.06) to ($0.71), maintaining a "Buy" rating with a $34.00 price target.
• As of August 12, the company's stock price was reported at $13.35, down by 1.8%, with a 1-year price range between $6.71 and $19.19.
• Five analysts have issued a buy rating for Maze Therapeutics, resulting in an average rating of "Buy" and a consensus price target of $25.60.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Equities researchers at HC Wainwright upped their Q3 2025 earnings estimates for shares of Maze Therapeutics in a research note issued on Wednesday, August 13th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings of ($0.71) per share for the quarter, up from their previous estimate of ($1.06). HC Wainwright has a "Buy" rating and a $34.00 price objective on the stock. HC Wainwright also issued estimates for Maze Therapeutics' Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($3.21) EPS, FY2026 earnings at ($2.73) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($1.16) EPS.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Wedbush initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company's stock. Based on data from MarketBeat, Maze Therapeutics presently has a consensus rating of "Buy" and an average target price of $25.60.

Maze Therapeutics Price Performance

Shares of MAZE traded up $0.10 during trading hours on Friday, hitting $13.45. The stock had a trading volume of 214,992 shares, compared to its average volume of 200,177. The business's 50-day moving average is $13.94. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently modified their holdings of the business. TRV GP IV LLC purchased a new stake in shares of Maze Therapeutics in the first quarter valued at about $66,874,000. Frazier Life Sciences Management L.P. purchased a new stake in shares of Maze Therapeutics in the first quarter valued at about $45,460,000. ARCH Venture Management LLC purchased a new stake in shares of Maze Therapeutics in the first quarter valued at about $45,362,000. Matrix Capital Management Company LP purchased a new stake in shares of Maze Therapeutics in the first quarter valued at about $27,373,000. Finally, Alphabet Inc. purchased a new stake in shares of Maze Therapeutics in the first quarter valued at about $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.